EUCTR2016-000073-21-GB进行中（未招募）1 期
A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Children < 12 years of age at time of informed consent with allowance for the following: for patients 12 17 years of age and who weigh < 40 kilograms (kg) at the time of informed consent(Cohort A only); and for patients < 2 years of age will be allowed to participate only after the protocol defined interim data review criteria are met (Cohort A only)
- •- Body weight > 3 kg at time of informed consent
- •- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures including the completion of applicable patient-reported outcome (PRO) questionnaires
- •- Caregivers must have the willingness and ability to comply with all study procedures including the completion of the bleed/medication questionnaire and applicable HRQoL questionnaires
- •- Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (i.e., >=5 BU)
- •- Requires treatment with bypassing agents
- •- For patients >= 2 years of age (Cohort A only): if on episodic bypassing agent regimen annualized bleeding rate (ABR) of >=6 ; or if on prophylactic bypassing agent regimen inadequately controlled or central venous access device (CVAD) placement medically not feasible or deemed unsafe
- •- For patients < 2 years of age determined by investigator to be in high unmet medical need
- •- Adequate hematologic, hepatic and renalfunctions
- •- Female patients of childbearing potential who have negative serum pregnancy test result and an agreement to remain abstinent or use contraceptive methods specified in the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 80
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Inherited or acquired bleeding disorder other than hemophilia A
- •- Ongoing (or plan to receive during the study) immune tolerance induction (ITI) therapy or prophylaxis treatment with FVIII. Patients awaiting initiation of ITI will be eligible and patients in whom ITI has failed will be eligible with a 72-hour washout period prior to the first emicizumab administration
- •- Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
- •- Other diseases (i.e., certain autoimmune diseases [e.g., systemic lupus erythematosus], cardiovascular disease) that may increase risk of bleeding or thrombosis
- •- Known infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus
- •- Patients who are at high risk for TMA (e.g., have a previous medical or family history of TMA), in the investigator’s judgment
- •- Use of systemic immunomodulators (e.g., interferon or corticosteroids) at enrollment or planned use during the study period
- •- Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study
- •- Inability (or unwillingness by caregiver) to receive (allow receipt of) blood or blood products (or any standard-of-care treatment for a life-threatening condition)
研究者
相似试验
进行中（未招募）
1 期
A PHASE III, OPEN-LABEL, MULTICENTRIC CLINICAL TRIAL OF A SINGLE ARM OF 16 LENGTHS OF TIME TO EVALUATE RETENTION WITH ELBASVIR / GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C CHRONIC GENOTYPES 1.4 WHO HAVE FAILED TO TREAT WITH A REGIME BASED ON AN INHIBITOR OF THE NS5AEUCTR2017-000432-34-ESFundación SEIMC-GESIDA
已完成
3 期
A clinical trial to study the effect of a combination product of Eberconazole 1% and Mometasone 0.1% in patients with inflamed cutaneous mycoses.CTRI/2009/091/001048Dr Reddys Laboratories Ltd Hyderabad India150
已完成
4 期
A Clinical trial to determine the efficacy of capsule in iron deficiency anemia patientsCTRI/2023/05/052772Ambtu Life Sciences Pvt Ltd60
进行中（未招募）
不适用
A Phase III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/ rhIGFBP-3), administered for 12 Months in Children and Adolescents with Growth Hormone Insensitive Syndrome (GHIS) such a Laron Syndrome.EUCTR2004-000644-25-ITINSMED INCORPORATED
尚未招募
3 期
A Study to check the effect of Oral OPC-34712 asMaintenance Treatment in Adults with SchizophreniaCTRI/2013/05/003640Otsuka Pharmaceutical Development Commercialization Inc1,000